EnteroMedics closes $16m follow-on

EnteroMedics (NSDQ:ETRM) yesterday said it netted $14.7 million from a follow-on offering it initially hoped would gross $35 million.

St. Paul, Minn.-based EnteroMedics initially planned to float 40.2 million shares at 87¢ apiece,for gross proceeds of $35 million. That offering was to have consisted of 1 ETRM share, plus Series A and Series B warrants. But the company was forced to cancel the issue after the NASDAQ Capital Market said wouldn’t approved the transaction.

Instead, EnteroMedics retooled the offering to 32 million shares at 50¢ apiece, comprised of 1 ETRM share plus Series A warrants.

Canaccord Genuity was the sole book-running manager, with Craig-Hallum Capital Group as co-manager and Northland Securities and Roth Capital Partners as financial advisors, EnteroMedics said.

The company won FDA approval for its flagship Maestro device in January 2015, following a mixed vote last year after the device failed to meet its efficacy endpoint in a clinical trial. It’s designed to use what EnteroMedics calls “vBloc therapy,” in which electrical pulses are used to block intra-abdominal vagus nerve signaling between the brain and stomach using a pacemaker-like device.

The company has said it plans to use the funds to further the commercialization of Maestro, which saw its 1st commercial implantation in May.

The post EnteroMedics closes $16m follow-on appeared first on MassDevice.

from MassDevice http://ift.tt/1D33KlL